Brief: Cytodyn Submits The First Of Three Main Sections Of HIV BLA To FDA Under Previously Authorized Rolling Review
16/11/2021 11:05
Nov 16 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN SUBMITS THE FIRST OF THREE MAIN SECTIONS OF HIV
BLA TO
FDA UNDER PREVIOUSLY AUTHORIZED ROLLING REVIEW
* CYTODYN INC - CLINICAL SECTION (LAST PORTION TO COMPLETE
HIV
BLA) EXPECTED TO BE SUBMITTED DURING Q1 2022
Source text for Eikon: ID:nGNX4M4y9d
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer